Jan 10, 2024
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Feb 18, 2021
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
Feb 10, 2021
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
Feb 04, 2021
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
Nov 23, 2020
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
Nov 05, 2020
Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference
Oct 30, 2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Oct 25, 2020
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
Oct 15, 2020
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
Sep 18, 2020
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
Sep 17, 2020
Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
Sep 03, 2020
Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual Conference
Aug 13, 2020
Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor
Aug 06, 2020
Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
May 15, 2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
May 07, 2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
Feb 25, 2020
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
Feb 15, 2020
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
Jan 14, 2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares